Peter Nyquist
Head of Investor Relations
Replay available
Elekta AB (publ) (STO: EKTA_B) Q1 2026 earnings conference call, held 2025-08-28. Replay captured from the company's public earnings webcast.

Head of Investor Relations
CEO
CFO
Analyst, Barclays
Analyst, Danske Bank
Analyst, SEB
Analyst, ABG
Analyst, Morgan Stanley
Analyst, Handelsbanken
Analyst, Bank of America
Analyst, Jeffreys
Hi and good morning everyone. My name is Peter Nyquist. I'm the Head of Investor Relations here at Elekta. With me here in Stockholm I have our CEO Jonas Belander and our CFO Tobias Hägglöf who will be presenting the results from the first quarter of this fiscal year 2025-2026. So we will start with the normal agenda with Jonas presenting some highlights from the development during the first quarter, as well as some achievements we have reached during the quarter. Then Tobias will bring us down to more details on the financials, and then we will have an outlook from Jonas by the end of presentation. And as always, after presentation, we will end with a Q&A. But before starting, I want to remind you that some of the information discussed on this call contains forward-looking statements. This can include projections regarding revenue, operating result, cash flow, as well as products and product development. These statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in the statements. With that said, I would like to hand over the word to you, Jonas. Please, Jonas. Thank you very much, Peter, and thank you all for attending this call. So we start with the key takeaways for the first quarter of fiscal year 2025-2026. The book-to-bill ratio came in at 1.05 in the first quarter. We saw a 1% order decline in constant exchange rate compared to last year. However, rolling 12-month book-to-bill remains at 1.09, reflecting a healthy business environment. Net sales increased by 3% in constant currencies, mainly driven by continued strong momentum in Europe, where our latest linear accelerator Electa Evo and our new software suite Electa One are gaining traction as online adaptive treatment capabilities continue to set ...